P. Putora (St. Gallen, Switzerland), J-P. Sculier (Brussels, Belgium)
An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed (Pem) for advanced non-small cell lung cancer (NSCLC)
U. Weinberg, I. Fresard, M. Kueng, R. Cathomas, M. Buess, M. Pless, Y. Palti, E. Kirson, D. Betticher (Haifa, Israel; Fribourg, Chur, Basel, Winterthur, Switzerland)
|   |
Swedish Lung Cancer Radiation Study Group: The value of induction chemotherapy for radiotherapy response in patients with non-small cell lung cancer
M. Sandelin, G. Holgersson, C. Janson, S. Ekman, M. Bergqvist, S. Bergström (Uppsala, Gävle, Sweden)
|  |
Cost-effectiveness analysis of three strategies of erlotinib treatment in non small-cell lung cancer: A prospective multicentric French study (ERMETIC)
I. Borget, J. Cadranel, A. Mauguen, E. Quoix, B. Coudert, J. Madeleine, E. Dansin, V. Westeel, A. Madroszyk, S. Friard, C. Daniel, F. Morin, J. P. Pignon, C. Chouaid (Villejuif, Paris, , Dijon, Caen, Lille, Besancon, Marseille, Saint-Cloud, France)
| |
Comparison between surgery and radiofrequency ablation for stage I non-small cell lung cancer
H. J. Han, S. R. Kim, S. J. Park, K. H. Min, H. Moon, M. H. Lee, C. R. Chung, K. H. Choi, H. B. Lee, Y. K. Rhee, M. H. Kim, G. Y. Jin, Y. C. Lee (Jeonju, Republic Of Korea)
| |
Impact of 3D conformal radiotherapy on lung function of patients with lung cancer: A prospective study
I. Enache, G. Noel, M. Oswald-Mammosser, M. Y. Jeung, E. Quoix, E. Urban-Kraemer, A. Charloux (Strasbourg, France)
| |
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines
K. S. Kim, B. K. Yoon, I. J. Oh, Y. C. Kim, Y. S. Kwon, Y. I. Kim, S. C. Lim, J. H. Lim, J. P. Jeong, H. J. Ban, S. Y. Chi, C. M. Park (Gwangju, , Suncheon, Republic Of Korea)
| |
C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib
I. CsToth, C. Mascaux, G. Anthoine, T. Berghmans, M. Paesmans, A. P. Meert, J. P. Sculier (Brussels, Belgium)
| |
Prognostic systems in advanced non small cell lung cancer (NSCLC): A validation study by the European Lung Cancer Working Party (ELCWP)
M. Paesmans, J. J. Laffite, T. Berghmans, J. Lecomte, A. Efremidis, V. Giner, A. Scherpereel, A. P. Meert, N. Leclercq, P. Van Houtte, J. P. Sculier (Brussels, Charleroi, Belgium; Lille, France; Athens, Greece; Valencia, Spain)
| |